Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 5,600 shares to two new employees, effective December 31, 2021. The options, priced at $6.43 per share, are part of an inducement package compliant with Nasdaq Listing Rule 5635(c)(4). Each option vests over four years, with a portion vesting upon the one-year employment anniversary. Immediate exercise is possible upon termination for good reason or without cause within a year of a change in control. Karyopharm focuses on developing innovative cancer therapies, notably XPOVIO®, for various malignancies.

Karyopharm Therapeutics (KPTI) has entered an exclusive licensing agreement with Menarini Group to commercialize NEXPOVIO (selinexor) across Europe and other global territories. In exchange, Karyopharm will receive a $75 million upfront payment and be eligible for up to $202.5 million in future milestones, plus royalties on net sales. NEXPOVIO is conditionally authorized in the EU for treating multiple myeloma patients who have undergone at least four prior therapies. The partnership aims to enhance patient access to this innovative cancer therapy.

Karyopharm Therapeutics (Nasdaq: KPTI) has signed an exclusive licensing agreement with Menarini Group for the commercialization of NEXPOVIO (selinexor) in Europe and other regions. Karyopharm will receive an upfront payment of $75 million and potential milestones of up to $202.5 million, plus royalties on sales. NEXPOVIO, already authorized in the EU for treating multiple myeloma, may expand to additional oncology indications. This partnership aims to enhance patient access to innovative cancer treatments across key global markets.

Karyopharm Therapeutics (KPTI) announced that its partner, Antengene Corporation, received conditional approval from China's NMPA for XPOVIO (selinexor) in combination with dexamethasone for relapsed or refractory multiple myeloma patients. This approval follows positive results from the Phase 2 STORM trial and Antengene's Phase 2 MARCH trial in China. The Phase 3 BENCH trial will serve as a confirmatory trial. CEO Richard Paulson highlighted the significance of this approval in providing new treatment options for patients. Karyopharm remains focused on expanding XPOVIO's availability globally.

Karyopharm Therapeutics (Nasdaq: KPTI) presented updated data from the Phase 2 ESSENTIAL study on selinexor for myelofibrosis patients at the ASH 2021 Annual Meeting. Results revealed that 40% of patients achieved a spleen volume reduction (SVR) of at least 35%, and 60% experienced an SVR of at least 25% after 24 weeks of treatment. The drug exhibited a favorable safety profile with manageable side effects. Additionally, the company has initiated a new Phase 2 study comparing selinexor to physician's choice in previously treated myelofibrosis patients.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the appointment of Peter K Honig, MD, MPH, to its Board of Directors effective December 3, 2021. Dr. Honig brings over 30 years of experience in drug development from leadership roles at Pfizer, Merck, and the FDA. He replaces Mikael Dolsten, who stepped down on December 2, 2021, due to competing demands. Dr. Honig expressed enthusiasm for contributing to Karyopharm's growth and advancing its cancer therapies. The company is focused on pioneering novel cancer treatments, including its lead drug, XPOVIO®.

Karyopharm Therapeutics (KPTI) has commenced a Phase 2 study (XPORT-MF-035) to assess the efficacy of oral selinexor in myelofibrosis patients previously treated with JAK inhibitors. The trial aims to enroll up to 112 patients, evaluating the primary endpoint of spleen volume reduction. This study follows promising results from the ESSENTIAL trial, where 33% of patients experienced significant SVR after 24 weeks of treatment. The company emphasizes its commitment to addressing unmet medical needs in serious conditions like myelofibrosis.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the completion of patient recruitment for the Phase 3 SIENDO study, evaluating selinexor for front-line maintenance therapy in advanced or recurrent endometrial cancer. With over 250 patients enrolled, the study aims to show improved progression-free survival rates. There are currently no approved maintenance therapies for this cancer type. Karyopharm expects to report top-line data by year-end 2021 or early 2022, which could demonstrate selinexor's therapeutic potential and impact future treatment options.

Karyopharm Therapeutics (Nasdaq: KPTI) announced on December 1, 2021, that its Compensation Committee granted stock options for 68,900 shares to 13 new employees, effective November 30, 2021. The options have an exercise price of $6.95 per share, equal to the closing price on the grant date. Each option vests over four years, with 25% vesting after one year, and can be exercised immediately upon termination under certain conditions. This move is part of Karyopharm's strategy to attract talent as it develops novel cancer therapies.